Drug Discovery for Neurodegeneration Conference

7^thANNUAL DRUG DISCOVERY FOR NEURODEGENERATION CONFERENCE:

An Intensive Course on Translating Research into Drugs

Presented by the Alzheimer's Drug Discovery Foundation

February 10-12, 2013 ● San Francisco, CA

HOME ● PROGRAM ● SPEAKERS ● SCHOLARSHIPS ● REGISTRATION ● ACCOMMODATIONS ● SPONSORSHIP ● SUPPORTERS ● CONTACT

PRELIMINARY PROGRAM

Sunday, February 10, 2013 All sessions will be held at the Hyatt at Fisherman's Wharf
2:00pm – 4:00	Registration
4:00 – 4:20	Welcome & Opening Remarks: Challenges and Opportunities in Academic Drug Discovery Howard Fillit, MD, Alzheimer’s Drug Discovery Foundation
4:20 – 5:05	Plenary: Transforming Drug Discovery for Complex Diseases: A Systems Biology Approach Piet van der Graaf, PhD, Pfizer Inc.
5:05 – 5:15	Q&A
5:15 – 5:20	Closing Remarks Howard Fillit, MD, Alzheimer's Drug Discovery Foundation
5:20 – 7:00	Welcome Reception and Poster Reception
Monday, February 11, 2013
8:00 am – 8:30	Continental Breakfast & Registration
8:30 – 8:35	Welcome and Opening Remarks Lorenzo M. Refolo, PhD, National Institute on Aging
8:35 – 8:50	Preclinical Therapeutics Development for Neurological Disorders: Funding and Resources Lorenzo M. Refolo, PhD, National Institute on Aging Rajesh Ranganathan, PhD, National Institute of Neurological Disorders and Stroke
I. Basics of Medicinal Chemistry Chair: D. Martin Watterson, PhD, Northwestern University
8:50 – 9:25	Overview: Medicinal Chemistry Rules of Thumb, Myths and Realities in CNS Drug Discovery D. Martin Watterson, PhD, Northwestern University
9:25 – 9:35	Q&A
9:35 – 10:10	Chemistry Essentials for Drug Discovery Biologists Jeff C. Pelletier, PhD, Fox Chase Chemical Diversity Center, Inc.
10:10 – 10:20	Q&A
10:20 – 10:40	Natural Products as Drug Starting Points Frank E. Koehn, PhD, Pfizer Inc.
10:40 – 10:50	Q&A
10:50 – 11:20	Break
II. Drug Discovery: From Screening to Clinical Candidate Chair: Kelly R. Bales, PhD, Pfizer Inc.
11:20 – 11:25	Session Overview Kelly R. Bales, PhD, Pfizer Inc.
11:25 – 11:45	Improving Clinical Success through Optimal Target Validation Kalpana M. Merchant, PhD, Eli Lilly and Company
11:45 – 11:55	Q&A
11:55 am – 12:15 pm	Trends in High Throughput Screening (HTS) Michelle Arkin, PhD, University of California San Francisco
12:15 – 12:25	Q&A
12:25 – 1:55	Lunch and Poster Session
1:55 – 2:15	Compound Optimization after HTS: From Hit to Lead Kurt R. Brunden, PhD, University of Pennsylvania
2:15 – 2:25	Q&A
2:25 – 2:45	Absorption, Distribution, Metabolism, Excretion and Toxicology (ADME-Tox) in Compound Refinement Katya Tsaioun, PhD, Pharma Launcher
2:45 – 2:55	Q&A
2:55 – 3:15	Designing a Therapeutic Animal Study Kelly R. Bales, PhD, Pfizer Inc.
3:15 – 3:25	Q&A
3:25 – 3:45	Break
3:45 – 4:05	Requirements for an IND and Early Considerations Edward G. Spack, PhD, Fast Forward, LLC
4:05 – 4:15	Q&A
4:15 – 4:35	An Academic Perspective on Drug Discovery Services: Centers & CROs Marcie Glicksman, PhD, Harvard NeuroDiscovery Center
4:35 – 4:45	Q&A
4:45 – 5:00	ADDF ACCESS Program and Closing Remarks Rachel Lane, PhD, Alzheimer's Drug Discovery Foundation
5:00 – 7:00	Networking Reception and Poster Session
Tuesday, February 12, 2013
8:00 – 9:00	Continental Breakfast
9:00 – 9:05	Welcome & Opening Remarks Diana Shineman, PhD, Alzheimer’s Drug Discovery Foundation
9:05 – 9:35	Plenary: Systematic Drug Repositioning for Neurodegenerative and Other Diseases Pankaj Agarwal, PhD, GlaxoSmithKline
9:35 – 9:45	Q&A
III. Strategies for Challenging CNS Targets Chair: Marcie Glicksman, PhD, Harvard NeuroDiscovery Center
9:45 – 9:50	Session Overview Marcie Glicksman, PhD, Harvard NeuroDiscovery Center
9:50 – 10:10	Challenges of Protein-Protein/Protein-Peptide Targets Jim Wells, PhD, University of California, San Francisco
10:10 – 10:20	Q&A
10:20 – 10:40	Utility of Stem Cells for Preclinical Drug Discovery Adam Rosenthal, PhD, iPierian Inc.
10:40 – 10:50	Q&A
10:50 – 11:10	Break
11:10 – 11:30	Peptide Therapeutics and Mechanisms for Intranasal Delivery Bruce Morimoto, PhD, Allon Therapeutics Inc.
11:30 – 11:40	Q&A
11:40 – 12:00	Developing Therapeutic Antibodies for Neurodegenerative Disease Ryan Watts, PhD, Genentech, Inc.
12:00 – 12:10	Q&A
12:10 – 1:10	Lunch and Poster Session
IV. Commercialization Strategies: Developing Science into Products Chair: Frank M. Longo, MD, PhD, Stanford University and PharmatrophiX
1:10 – 1:15	Session Overview Frank M. Longo, MD, PhD, Stanford University and PharmatrophiX
Panel Presentation and Discussion
1:15 – 1:30	Creative Pharma-Academia Partnership Models for Accelerating Drug Discovery Teri Melese, PhD, University of California, San Diego
1:30 – 1:45	Landscape of Funding Opportunities for Biotechnology Companies Melinda Richter, MBA, Prescience International
1:45 – 2:00	Starting Your Own Biotech: Challenges and Pitfalls Frank M. Longo, MD, PhD, Stanford University and PharmatrophiX
2:00 – 2:15	How Foundations Can Bridge the Funding and Resources Gap Kuldip Dave, PhD, Michael J. Fox Foundation for Parkinson’s Research
2:15 – 2:30	Partnerships and Collaboration: Translating Early Space Innovation into Therapeutics Steven Bartz, PhD, Merck & Co., Inc.
2:30 – 3:00	Open Discussion
3:00 – 3:15	Closing Remarks Howard Fillit, MD, Alzheimer's Drug Discovery Foundation